This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hellström, I. Articles by Hellström, K. E. Search for Related Content PubMed PubMed Citation Articles by Hellström, I. Articles by Hellström, K. E.

Monoclonal Mouse Antibodies Raised against Human Lung Carcinoma¹

ONCOGEN, Seattle, Washington 98121 [I. H., D. H., P. L., J. P. B., V. B., K. E. H.], and Departments of Microbiology/Immunology [I. H.] and Pathology [K. E. H.], University of Washington, Seattle, Washington 98195

We have evaluated approximately 10,000 monoclonal antibodies (MoAb) resulting from 25 hybridizations of spleen cells from mice immunized with cells from human non-small cell lung carcinoma or fetal lung. The spleen cells were hybridized with NS-1 myeloma cells, and the resulting hybridomas were screened for production of MoAb to non-small cell lung carcinoma by binding assays with either cell extracts or cells growing in culture, followed by immunohistology on frozen sections. Fourteen MoAb had relative specificity for non-small cell lung carcinoma versus normal tissues. Three of these MoAb (L3, L6, L17) also reacted with most carcinomas of the breast and colon, and two MoAb (L20 and L22) reacted with the four samples of small cell lung carcinoma tested. No MoAb defined an antigen of absolute tumor specificity, and no MoAb reacted substantially more with adenocarcinoma than squamous cell carcinoma of the lung (or vice versa). Five MoAb were Ig G1, two were Ig G2a, and the remaining seven were Ig M. Seven MoAb (L5, L6, L15, L17, L20, L22, L23) could bind to the cell surface. Three MoAb (L6, L15, L17) defined carbohydrate antigens, and three (L3, L5, L20) were to protein antigens, while the antigens to which the remaining MoAb are directed have not been identified. Six MoAb could bind to tumor cells in Carnoy-fixed paraffin-embedded sections. An intercellular variability in antigen expression was detected with all 14 MoAb. At least two of the MoAb, L6 and L20, are good candidates for preclinical testing in view of their high level of tumor selectivity, as shown by both immunohistology and binding assays with living cells.

¹ This work was supported by ONCOGEN.

² To whom requests for reprints should be addressed, at ONCOGEN, 3005 First Avenue, Seattle, WA 98121.

Received 2/10/86. Revised 4/28/86. Accepted 5/ 5/86.

This article has been cited by other articles:

				T. Lekishvili, E. Fromm, M. Mujoomdar, and F. Berditchevski The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility J. Cell Sci., March 1, 2008; 121(5): 685 - 694. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, G. L. DeNardo, A. Natarajan, L. A. Miers, A. R. Foreman, C. Gruettner, G. N. Adamson, and R. Ivkov Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF-Induced Thermoablative Therapy for Human Breast Cancer in Mice J. Nucl. Med., March 1, 2007; 48(3): 437 - 444. [Abstract] [Full Text] [PDF]

				S. J. DeNardo, G. L. DeNardo, L. A. Miers, A. Natarajan, A. R. Foreman, C. Gruettner, G. N. Adamson, and R. Ivkov Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy Clin. Cancer Res., October 1, 2005; 11(19): 7087s - 7092s. [Abstract] [Full Text] [PDF]

				Y.-R. Kao, J.-Y. Shih, W.-C. Wen, Y.-P. Ko, B.-M. Chen, Y.-L. Chan, Y.-W. Chu, P.-C. Yang, C.-W. Wu, and S. R. Roffler Tumor-associated Antigen L6 and the Invasion of Human Lung Cancer Cells Clin. Cancer Res., July 1, 2003; 9(7): 2807 - 2816. [Abstract] [Full Text] [PDF]

				P. A. Burke, S. J. DeNardo, L. A. Miers, K. R. Lamborn, S. Matzku, and G. L. DeNardo Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts Cancer Res., August 1, 2002; 62(15): 4263 - 4272. [Abstract] [Full Text] [PDF]

				M. Papetti and I. M. Herman Controlling Tumor-Derived and Vascular Endothelial Cell Growth : Role of the 4F2 Cell Surface Antigen Am. J. Pathol., July 1, 2001; 159(1): 165 - 178. [Abstract] [Full Text] [PDF]

				N. Scholler, N. Fu, Y. Yang, Z. Ye, G. E. Goodman, K. E. Hellstrom, and I. Hellstrom Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma PNAS, September 28, 1999; 96(20): 11531 - 11536. [Abstract] [Full Text] [PDF]

				K. A. Foon, J. Yannelli, and M. Bhattacharya-Chatterjee Colorectal Cancer as a Model for Immunotherapy Clin. Cancer Res., February 1, 1999; 5(2): 225 - 236. [Full Text] [PDF]

				S. J. DeNardo, D. L. Kukis, L. A. Kroger, R. T. O'Donnell, K. R. Lamborn, L. A. Miers, D. G. DeNardo, C. F. Meares, and G. L. DeNardo Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts PNAS, April 15, 1997; 94(8): 4000 - 4004. [Abstract] [Full Text] [PDF]

				M Better, C. Chang, R. Robinson, and A. Horwitz Escherichia coli secretion of an active chimeric antibody fragment Science, May 20, 1988; 240(4855): 1041 - 1043. [Abstract] [PDF]